Leachianone G

Leachianone G

SCHEMBL6544629

CC(C)=CCc1c(O)cc(O)c2c1OC(c1ccc(O)cc1O)CC2=O

nearest known ligand 0.81

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 2/20 0.81
ABCG2 Q9UNQ0 6/20 0.77
ESR1 P03372 3/20 0.77
ESR2 Q92731 2/20 0.77
MAOA P21397 2/20 0.77
CACNA1G O43497 2/20 0.77
CACNA1H O95180 2/20 0.77
AKR1B10 O60218 2/20 0.77
AKR1B1 P15121 2/20 0.77
PDE5A O76074 1/20 0.77
CYP19A1 P11511 2/20 0.76
MAOB P27338 1/20 0.75
BACE1 P56817 2/20 0.71
SLC5A1 P13866 1/20 0.71
SLC5A2 P31639 1/20 0.71
ACHE P22303 2/20 0.70
CYP3A4 P08684 1/20 0.70
CYP2D6 P10635 1/20 0.70
CYP2C9 P11712 1/20 0.70
CYP2C19 P33261 1/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Leachianone G SCHEMBL6544631 1.00 IDO1 (0.81) IDO1ABCG2ESR1ESR2MAOA
Leachianone G SCHEMBL31237622 1.00 IDO1 (0.81) IDO1ABCG2ESR1ESR2MAOA
SCHEMBL17626644 0.91 ABCG2 (0.79) IDO1ABCG2ESR1ESR2MAOA
SCHEMBL27013448 0.91 ABCG2 (0.79) IDO1ABCG2ESR1ESR2MAOA
SCHEMBL29808777 0.91 ABCG2 (0.79) IDO1ABCG2ESR1ESR2MAOA
SCHEMBL17626647 0.91 ABCG2 (0.79) IDO1ABCG2ESR1ESR2MAOA
SCHEMBL29454740 0.90 IDO1 (0.75) IDO1ABCG2ESR1ESR2MAOA
SCHEMBL564110 0.89 IDO1 (1.00) IDO1ABCG2ESR1ESR2MAOA
SCHEMBL17626616 0.89 IDO1 (1.00) IDO1ABCG2ESR1ESR2MAOA
Sophoraflavanone L SCHEMBL30766211 0.87 IDO1 (0.71) IDO1ABCG2ESR1ESR2MAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118370763-A Application of isopentenyl flavonoid compound in kuh-seng extract in preparation of product for preventing and treating pathogenic bacteria of dairy cows 山东方舟生物科技有限公司 2024-07-23 CN claimed
CN-118304334-A Preparation and application of traditional Chinese medicine fructus rhodomyrti liver protection active ingredient 北京工业大学 2024-07-09 CN claimed
US-11517556-B2 Composition for BKCa channel activation GWANGJU INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2022-12-06 US claimed
US-20200069640-A1 COMPOSITION FOR BKCA CHANNEL ACTIVATION GWANGJU INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2020-03-05 US claimed
US-20190083456-A1 COMPOSITION FOR BKCA CHANNEL ACTIVATION GWANGJU INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2019-03-21 US claimed
EP-1294388-B1 EXTRACTS FROM SOPHORA SPECIES, METHOD FOR PRODUCING THE SAME AND THEIR USE SCHWABE WILLMAR GMBH & CO (DE) 2004-01-07 EP claimed
CN-118370763-B Application of isopentenyl flavonoid compound in kuh-seng extract in preparation of product for preventing and treating pathogenic bacteria of dairy cows 山东方舟生物科技有限公司 2024-10-08 CN disclosed
CN-118370763-A Application of isopentenyl flavonoid compound in kuh-seng extract in preparation of product for preventing and treating pathogenic bacteria of dairy cows 山东方舟生物科技有限公司 2024-07-23 CN disclosed
CN-114146083-B Sophora japonica extract and active ingredient and application thereof in preparation of products for treating glycolipid metabolism comprehensive disorder 天津科技大学 2024-05-24 CN disclosed
US-11517556-B2 Composition for BKCa channel activation GWANGJU INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2022-12-06 US disclosed
US-11479537-B2 T-type calcium channel inhibitor KINKI UNIVERSITY (JP) 2022-10-25 US disclosed
EP-3000465-B1 T-TYPE CALCIUM CHANNEL INHIBITOR UNIV KINKI (JP) 2021-03-31 EP disclosed
US-20200308132-A1 T-TYPE CALCIUM CHANNEL INHIBITOR NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (JP) 2020-10-01 US disclosed
US-10633358-B2 T-type calcium channel inhibitor KINKI UNIVERSITY (JP) 2020-04-28 US disclosed
US-20200069640-A1 COMPOSITION FOR BKCA CHANNEL ACTIVATION GWANGJU INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2020-03-05 US disclosed
US-20190083456-A1 COMPOSITION FOR BKCA CHANNEL ACTIVATION GWANGJU INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2019-03-21 US disclosed
US-20180132516-A1 POSITIVE ALLOSTERIC MODULATORS OF SWEET TASTE SENSORYGEN INC (US) 2018-05-17 US disclosed
US-20180065947-A1 T-TYPE CALCIUM CHANNEL INHIBITOR UNIV KINKI (JP) 2018-03-08 US disclosed
US-20160096815-A1 T-TYPE CALCIUM CHANNEL INHIBITOR KINKI UNIVERSITY (JP) 2016-04-07 US disclosed
EP-3000465-A1 T-TYPE CALCIUM CHANNEL INHIBITOR Kinki University (JP) 2016-03-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160096815-A1 T-TYPE CALCIUM CHANNEL INHIBITOR CACNA1G, CACNA1H, CACNA1I IDO1 3029/4885ABCG2 1660/4885ESR1 3507/4885
US-20200069640-A1 COMPOSITION FOR BKCA CHANNEL ACTIVATION KCNAB1, KCNN3, KCNC1 IDO1 3614/4885ABCG2 2102/4885ESR1 3513/4885
US-20180065947-A1 T-TYPE CALCIUM CHANNEL INHIBITOR CACNA1G, CACNA1H, CACNA1I IDO1 3036/4885ABCG2 1755/4885ESR1 3527/4885
US-11517556-B2 Composition for BKCa channel activation KCNAB1, KCNN3, KCNC1 IDO1 3614/4885ABCG2 2102/4885ESR1 3513/4885
US-11479537-B2 T-type calcium channel inhibitor CACNA1H, CACNA1I, CACNA1G IDO1 1814/4885ABCG2 1721/4885ESR1 3841/4885
US-20190083456-A1 COMPOSITION FOR BKCA CHANNEL ACTIVATION KCNAB1, KCNN3, KCNC1 IDO1 3614/4885ABCG2 2102/4885ESR1 3513/4885
US-20200308132-A1 T-TYPE CALCIUM CHANNEL INHIBITOR CACNA1H, CACNA1I, CACNA1G IDO1 1814/4885ABCG2 1721/4885ESR1 3841/4885
US-10633358-B2 T-type calcium channel inhibitor CACNA1G, CACNA1H, CACNA1I IDO1 3036/4885ABCG2 1755/4885ESR1 3527/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.